0PT.SG - Prothena Corp PLC
| Previous close | 65.00 |
| Open | 64.50 |
| Bid | 67.00 x 300000 |
| Ask | 67.50 x 300000 |
| Day's range | 64.50 - 65.50 |
| 52-week range | 21.38 - 71.00 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
Prothena Corporation plc (NASDAQ:PRTA) Analysts Just Trimmed Their Revenue Forecasts By 29%
One thing we could say about the analysts on Prothena Corporation plc ( NASDAQ:PRTA ) - they aren't optimistic, having...
- Zacks
Prothena (PRTA) Q1 Earnings and Revenues Miss Estimates
Prothena (PRTA) reports a wider loss in the first quarter. The company makes considerable pipeline progress.
- Zacks
Prothena (PRTA) Reports Q1 Loss, Lags Revenue Estimates
Prothena (PRTA) delivered earnings and revenue surprises of -7.23% and 85.51%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Analysts Estimate Prothena (PRTA) to Report a Decline in Earnings: What to Look Out for
Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
Companies Like Prothena (NASDAQ:PRTA) Can Afford To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
- Zacks
Walgreens (WBA) Declares Partnership With Prothena Corporation
Walgreens (WBA) collaborates with Prothena Corporation to support patient awareness, participation and representation in a clinical trial of Prothena's Alzheimer's drug candidate, PRX012.
- Zacks
Prothena (PRTA) Gains 29% in One Year: Will the Momentum Continue?
Prothena (PRTA) surges 29% in the past one year as investors are optimistic on its promising Alzheimer's Disease pipeline.
- Simply Wall St.
Analysts Just Made A Major Revision To Their Prothena Corporation plc (NASDAQ:PRTA) Revenue Forecasts
Market forces rained on the parade of Prothena Corporation plc ( NASDAQ:PRTA ) shareholders today, when the analysts...
- Zacks
Prothena (PRTA) Q4 Earnings and Revenues Beat Estimates
Prothena (PRTA) reports better-than-expected results for the fourth quarter. The company makes considerable pipeline progress.
- Simply Wall St.
Prothena (NASDAQ:PRTA) shareholder returns have been strong, earning 299% in 3 years
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
- Zacks
Biogen (BIIB) Down on Report of Death in Alzheimer's Study
Investor confidence in Biogen (BIIB) is rattled following reports of a study participant's death who was administered its Alzheimer's disease (AD) antibody in clinical studies.
- Zacks
Prothena (PRTA) Earns Milestone Payment From Novo Nordisk
Prothena (PRTA) earns a $40 million milestone payment from Novo Nordisk following the progress of NNC6019 in a phase II study for the treatment of ATTR cardiomyopathy.
- Simply Wall St.
Prothena Third Quarter 2022 Earnings: Misses Expectations
Prothena ( NASDAQ:PRTA ) Third Quarter 2022 Results Key Financial Results Net loss: US$45.8m (down by 142% from...
- Simply Wall St.
Companies Like Prothena (NASDAQ:PRTA) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- Zacks
Prothena's (PRTA) Q3 Earnings Miss, Revenues Decline Y/Y
Prothena (PRTA) incurs a loss in the third quarter while revenues miss estimates.
- Zacks
Prothena (PRTA) Reports Q3 Loss, Lags Revenue Estimates
Prothena (PRTA) delivered earnings and revenue surprises of -212.90% and 94.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
LLY & PRTA in Spotlight on BIIB-Eisai's AD Drug Data
The success of Biogen (BIIB)-Eisai's AD candidate in a big phase III study makes investors optimistic about the prospects of other AD candidates as well.
- Motley Fool
Why Biogen, Lilly, and Prothena Stocks Are Skyrocketing Today
Shares of Biogen (NASDAQ: BIIB) were skyrocketing 36% as of 11:10 a.m. ET on Wednesday. The huge gain came after the company and its partner Eisai (OTC: ESALY) announced positive results on Tuesday from their late-stage Clarity AD study evaluating lecanemab in treating Alzheimer's disease. The news also propelled two stocks of other drugmakers developing Alzheimer's disease drugs significantly higher.
- Zacks
Prothena (PRTA) Down 16.9% Since Last Earnings Report: Can It Rebound?
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Prothena (PRTA) Q2 Earnings Miss, Pipeline Progress in Focus
Prothena (PRTA) incurs a loss in the second quarter while revenues miss estimates.
- Zacks
Prothena (PRTA) Reports Q2 Loss, Misses Revenue Estimates
Prothena (PRTA) delivered earnings and revenue surprises of -72.55% and 93.48%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.
Prothena (NASDAQ:PRTA) delivers shareholders strong 57% CAGR over 3 years, surging 6.6% in the last week alone
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...
- Simply Wall St.
Prothena Corporation plc's (NASDAQ:PRTA) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
With its stock down 30% over the past three months, it is easy to disregard Prothena (NASDAQ:PRTA). However, a closer...
- Zacks
Why Is Epizyme (EPZM) Up 51.7% Since Last Earnings Report?
Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
